Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Nucala (mepolizumab) is a prescription drug used to treat a severe type of asthma and certain other inflammatory conditions. Nucala comes as an injection that you give under your skin. Nucala ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Get Instant Summarized Text (Gist) The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and a blood eosinophil count ≥150 ...

Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate ...

reinforced the efficacy of Nucala (mepolizumab) in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, irrespective of whether they ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients receiving mepolizumab vs. placebo had a ...